Goyal meets UK Secretary of State for Business and Trade (See 'Corp Brief') Access Control & AI-Enabled CCTV Systems to streamline Passenger Flow at Railway stations (See 'Corp Brief') IPR - Order passed by Controller of Patents, which lacks independent analysis and is verbatim reproduction of submissions of one party or recommendations of Opposition Board, is procedurally flawed: HC (See 'Legal Desk') Gut Microbiota and Probiotic Science Foundation organises 16th India Probiotic Symposium (See 'Corp Brief') IPR - Overall appearance at first impression is crucial to identify passing off, and meticulous side-by-side dissection is not necessary and trade dress has to be judged as whole: HC (See 'Legal Desk') DPIIT signs MoU with fuel-tech company to support startups (See 'Corp Brief') IBC - Interim arrangement directing parties to maintain status quo, thereby preventing any alteration to nature of principal asset or creation of further third-party interests, should be continued until final disposal by NCLT: SC (See 'Legal Desk') National Council for Cement signs MoU to strengthen skill development (See 'Corp Brief') Misc - Non-public servant can be proceeded against when initial case is registered u/s 13 of PC Act by virtue of Section 107 of IPC: SC (See 'Legal Desk') India preparing for global role in shift towards 'greener' future: MoS (See 'Corp Brief') IBC - Failure to exercise option of higher bid within prescribed timeline results in valid conclusion of auction in favour of highest bidder: NCLAT (See 'Legal Desk') Oriental Insurance crosses Rs 20,000 crore in Gross Premium (See 'Corp Brief') IBC - Non-inclusion of claim in resolution plan results in its extinguishment, and any claim which is not expressly included in resolution plan, and which is not expressly barred as per such plan, cannot be inferred: SC (See 'Legal Desk') 10,000 contributors onboarded on Bhashini Samudaye (See 'Corp Brief') PMLA - Recourse to LOC can be taken by investigating agency in cognizable offences if accused is deliberately evading arrest or not appearing in trial court despite Non-Bailable Warrants: HC (See 'Legal Desk') Supreme Court Clears Path For Single Insolvency Proceedings Against Linked Group Companies (See CORP EINSICHT)

Print

NPPA monitors prices of scheduled & non-scheduled medicines

Published: Jul 30, 2024

By TIOLCorplaws News Service

NEW DELHI, JULY 30, 2024: AS per the provisions of Drugs (Prices Control) Order, 2013 (DPCO, 2013), formulations listed in Schedule-I of the DPCO are defined as scheduled formulation under section 2(1)(zb) of DPCO, 2013. Formulations not included in Schedule-I are defined under Para 2(1)(v) of DPCO, 2013 as non-scheduled formulation. Thus, both schedule and non-schedule drugs are covered under DPCO, 2013. 

As per the extant provisions of DPCO, 2013, the ceiling prices of scheduled medicines are revised annually on the basis of Wholesale Price Index (WPI) (all commodities) for preceding calendar year by National Pharmaceutical Pricing Authority (NPPA), on or before 1st April of every year and is notified by the Government on the 1st day of April every year. The details of price fixed by NPPA are available at NPPA's website i.e. nppaindia.nic.in.  In case of non-scheduled formulation (branded or generic), as per para 20 of DPCO, 2013, no manufacturers can increase Maximum Retail Price (MRP) by more than 10% of MRP during preceding 12 months.  The maximum permissible increase in prices, as per the provisions of DPCO, 2013 for scheduled and non-scheduled drugs may or may not be availed by their respective manufacturers based on commercial considerations and market dynamics.

Under the Drugs and Cosmetics Act, 1945 and Rules thereunder, manufacturers of drugs are required to comply with conditions of manufacturing licence and the requirements of Good Manufacturing Practices (GMP).  As per the Drugs Rules, 1945, the manufacturing, testing, labeling, packaging, storage and distribution are required to be carried out in compliance with the conditions of license including the Good manufacturing practices (GMP) prescribed under the Schedule M of the Drugs Rules, 1945. In case of violation, the Licensing Authority is empowered to take action as per the said Act and Rules.

NPPA monitors the prices of scheduled as well as non-scheduled medicines under DPCO, 2013.  Action is taken against companies, found selling formulations at prices higher than the permissible price, and the overcharged amount is recovered from the company as per the relevant provisions of the DPCO, 2013. During the financial year 2023-24, Rs. 72.73 crore was recovered from the defaulting companies.

This information was given by the Union Minister of State for Chemicals and Fertilizers Anupriya Patel in Rajya Sabha in reply to a question today.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.